GHK-CU 50 mg/10 ml Spray
$55.23$61.38 (-10%)
GHK-CU 50 mg/10 ml Spray: GHK-Cu is a copper complex associated with the tripeptide glycyl-histidyl-lysine. The copper designation is chemically meaningful: it distinguishes a metal-associated material from the uncomplexed peptide. Reference databases contain different representations of copper complexes, so the specific reference record and supplied chemical form both matter. This listing uses a spray-format presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.
GHK-CU 50 mg/10 ml Spray Australia
GHK-CU 50 mg/10 ml Spray is listed at AU Peptides Shop in a spray-format presentation. This page brings together the compound identity, reference chemistry and laboratory considerations relevant to this specific catalogue entry. It is intended exclusively for controlled in vitro laboratory research, not personal use.
Product description
GHK-Cu is a copper complex associated with the tripeptide glycyl-histidyl-lysine. The copper designation is chemically meaningful: it distinguishes a metal-associated material from the uncomplexed peptide. Reference databases contain different representations of copper complexes, so the specific reference record and supplied chemical form both matter.
GHK, GHK-Cu and AHK-Cu are not interchangeable names. A peptide assay alone may not fully describe copper content or coordination, and a metal measurement alone does not identify the peptide ligand. Keep these analytical questions separate.
Chemical information and molecular structure
| Reference designation | GHK-Cu |
|---|---|
| Selected reference species | Prezatide copper |
| Reference molecular formula | C14H23CuN6O4+ |
| Reference molecular weight | 402.92 g/mol |
| Reference identifier | PubChem CID 71587328 |
| Sequence information | Peptide ligand: Gly-His-Lys; copper complex composition is specified separately |
View the reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied GHK-CU 50 mg/10 ml Spray.
Reference formula and molecular weight depend on the represented chemical species. Counterions, hydration, oxidation state, terminal modifications and formulation ingredients can change the relationship between a database molecule and the supplied material. Use the named reference species for structural comparison, and use the batch specification for the actual product composition.
Research applications and experimental scope
- Copper–peptide identity and coordination studies.
- Peptide and metal-content characterisation.
- Evaluation of complex integrity in defined matrices.
- Analytical comparison of peptide-containing formulations.
These are laboratory research topics and analytical objectives, not claims that the supplied product has achieved a biological result. Define the experimental question, model and acceptance criteria before comparing materials. A literature observation made with a different sequence, formulation or model cannot establish the performance of this catalogue item.
Analytical characterisation
For GHK-Cu, peptide-ligand identity and copper characterisation are complementary measurements. A chromatographic result for the organic ligand does not automatically establish metal association, while an elemental copper result does not identify the ligand. The analytical plan should state which chemical species the method is intended to measure.
Buffer composition, pH and competing ligands can affect the species present in a test matrix. Use qualified reference material and appropriate matrix controls when comparing complex-containing preparations. Distinguish the nominal complex label, measured peptide content and measured copper content rather than combining them into one unsupported purity statement.
Laboratory model and control considerations
An in vitro experiment with GHK-Cu should distinguish the test-material response from effects of the vehicle, assay matrix and any additional ingredients. Include the controls appropriate to the study design, and keep the reference standard and test sample traceable to their own preparation records. Where a readout depends on cell viability or matrix composition, assess those factors independently of the primary measurement.
Record the sample identity, selected product option, preparation history and analytical method used for the comparison. Repeatability within one run does not by itself establish specificity or transferability to another model. Report observations within the limits of the experimental system rather than treating an in vitro result as evidence of a clinical benefit.
Supplied format and product specifications
| Product name | GHK-CU 50 mg/10 ml Spray |
|---|---|
| Catalogue format | spray-format presentation |
| Quantity wording in listing | 50 mg / 10 ml |
| Purity / certification | Refer to the relevant batch report; no percentage or certification is assigned without product documentation. |
A spray-format product is a finished presentation. Total ingredient mass, total liquid volume and any documented actuation specification are separate measurements. Do not describe the finished spray as lyophilized powder or infer an amount per actuation from the bottle title alone. Formulation components can affect laboratory sample recovery and assay interference.
Solubility and matrix compatibility
For GHK-Cu, use product-specific solubility information and a laboratory method appropriate to the selected presentation. Apparent dispersion is not necessarily complete dissolution, and a visually clear preparation does not establish chemical stability. Assess recovery and matrix compatibility using the measurement required for your experiment.
Where the product contains additional ingredients, distinguish dissolution of the reference compound from extraction of the finished formulation. Record the documented matrix and any observed interference so another analyst can interpret the result. No universal solvent, solubility limit or preparation protocol is assigned from this catalogue name.
Storage and handling
Use the storage conditions specified for the supplied GHK-CU 50 mg/10 ml Spray batch and presentation. A universal freezer temperature, refrigeration interval or prepared-sample expiry is not assigned from the compound name alone. Obtain the relevant product guidance when storage or sample stability is an acceptance criterion for your work.
Maintain traceable labels and document the handling history relevant to the study. Assess changes in appearance, analytical profile or recovery against a validated method rather than assuming that an unchanged label establishes stability. Aseptic laboratory technique does not by itself demonstrate that a research product is sterile; sterility and related quality attributes require their own evidence.
Related catalogue comparisons
- GHK-Cu Copper Peptide (Copper Tripeptide-1) — Same named compound(s), different format.
- BPC157 10mg+GHK-CU 50mg+TB500 10mg Glow blend — Shares a named component; composition differs.
- BPC-157 10 mg+GHK-CU 100 mg+TB-500 10 mg Spray 10 ml — Shares a named component; composition differs.
- BPC-157+TB 500+GHK-Cu+KPV – Klow blend — Shares a named blend component; composition differs.
Compare the exact compound, form and quantity in each linked listing. These catalogue relationships do not establish interchangeable materials or recommend combined use.
Australian research enquiries
For GHK-CU 50 mg/10 ml Spray in Australia, include the complete listing name, required option and any analytical documentation requirements when you contact AU Peptides Shop. Browse the research catalogue for other individually specified materials. Current purchasing options show price and availability; batch evidence should be reviewed separately.
Scientific references
Research compliance notice
For controlled in vitro laboratory research only. Not for human or veterinary use. This description provides scientific reference information and does not recommend dosing, administration or treatment. Research-use labelling does not establish regulatory approval or permission for a particular activity under Australian therapeutic-goods requirements.
